Evotec has received a US$5m milestone payment from Bristol Myers Squibb following the US Food and Drug Administration’s ...

Teva Pharmaceuticals has announced new real-world data showing that AUSTEDO (deutetrabenazine) tablets and AUSTEDO XR ...

Gastro-resistant mercaptamine, marketed as Procysbi, has been accepted for use within NHS Scotland for the treatment of ...

MSD has announced positive results from its phase 3 CORALreef Lipids trial, showing that enlicitide decanoate, an investigational oral PCSK9 inhibitor, significantly reduced low-density lipoprotein ...

Heidelberg Pharma has reported encouraging progress in its phase 2/2a trial of HDP-101 (INN: pamlectabart tismanitin), its ...

The Christie NHS Foundation Trust has completed a four-month digital transformation project using Netcall’s Liberty Spark to ...

With a favourable safety profile and consistent activity across tumour types, agenT-797 is now poised to enter phase 2 trials. MiNK believes the therapy could redefine treatment for patients with ...

MND isn’t incurable, it’s underfunded ...

Women’s health issues have historically been under-researched, marginalised and underserved. This systemic neglect has led to ...

Rebuilding the clinical trials landscape in the UK ...

What is, exactly, going on with the NHS at the moment? You could be forgiven for thinking the fireworks of this summer’s ...

2025 is not just another year in pharma – it’s a turning point. The industry is riding a wave of scientific breakthroughs, regulatory agility and patient-centric innovation that’s reshaping the very ...